AUTL News and Press, Autolus Therapeutics plc From 03/14/23

2023-03-14 07:20:23 ET A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, Autolus Therapeutics ( NASDAQ: AUTL ) said that Dr. Lucinda Crabtree has provided notice of her resignation as CFO to pursue a new opportu...

- Dr. Lucinda Crabtree to step down with effect from Q3 2023 – - Search for new CFO has been initiated - LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cel...

LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today and following recent events with Silicon Valley Bank, announced that the company has no business relati...

2023-03-07 14:04:15 ET Autolus Therapeutics plc (AUTL) Q4 2022 Earnings Conference Call March 7, 2023 8:30 am ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Julia Wilson - Consilium Strategic Advisors ...

2023-03-07 07:06:30 ET Autolus Therapeutics press release ( NASDAQ: AUTL ): FY GAAP EPS of -$1.57 beats by $0.06 . Revenue of $6.36M (+173.0% Y/Y) misses by $4.47M . For further details see: Autolus Therapeutics GAAP EPS of -$1.57 beats by $0.06, revenue ...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track for next data update at a medical conference in mid-2023 with a Biologics L...

2023-03-06 11:19:39 ET Autolus Therapeutics ( NASDAQ: AUTL ) is scheduled to announce FY earnings results on Tuesday, March 7th, before market open. The consensus EPS Estimate is -$1.57 (+20.3% Y/Y) and the consensus Revenue Estimate is $10.83M (+364.8% Y/Y). Over the ...

2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...

LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2022 financial results and operational h...

Summary Primary endpoint met with interim analysis released from phase 1b/2 FELIX study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia; 70% Overall Remission Rate achieved. Recently released positive interim analysis results with obe-ce...